Seeking Alpha

Chimera Researc...'s  Instablog

Chimera Research Group
Send Message
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA).... More
My company:
Chimera Research Group
My blog:
Chimera Blog
My book:
The Biotech Trader Handbook (2nd Edition)
  • Four Emerging Taiwan Drug Developers 5 comments
    Aug 10, 2010 4:06 PM
    Taiwan’s drug makers have largely focused on generics; few are in the business of developing novel medicines. This is partially due to the large resources required for such an endeavor combined with Taiwan’s small market potential. To justify the costs of developing a new drug, companies must have the ability to navigate across borders in the hopes of selling their drugs in far larger markets. Few have this capacity.

    Of the ten largest drug manufacturers in Taiwan, four are publicly traded, none of which are drug developers. The largest of these, Yung Shin Pharma Industries, sells products ranging from generics to cosmetics, and has a market cap of over $8 billion. The other three are China Chemical & Pharmaceutical, Standard Chemical & Pharmaceutical, and Sinphar Pharmaceutical. The first two are makers of generic drugs and the latter makes Chinese herbal medicines and nutraceuticals.

    Let’s take a look at four companies that have made the leap. All are private, all are drug developers, but each does drug development slightly differently. These are some of the leading edge biotechs in Taiwan, helping to reshape the industry.

    TaiGen Biotech resembles a US biotech in that it is a pure-play drug developer. It has two compounds in US clinical trials- Nemonoxacin (TG-873870), an antibiotic licensed from Proctor and Gamble for the treatment of community acquired pneumonia and diabetic foot infections is in Phase II, and internally discovered TG-0054, a CXCR4 antagonist, is being tested in certain cancer indications. The company is well capitalized, having raised $37 million from investors in January 2009. It has operations in the US, China, and Taiwan.

    TTY Biopharm remade itself from a generic drug manufacturer and distributor into a global company with a focus on developing new drugs. Founded in 1960, it slowly improved its technology over the decades through technology transfers from western pharmaceutical companies. It later partnered with then tiny Taiwan Liposome Company to develop and sell Lipo-Dox in 1997, transforming itself into a seller of branded generics. It now continues to partner with early stage companies in their drug development, providing technical resources and financial support.

    AbGenomics has an early stage pipeline of antibody therapeutics. Its most advanced product, AbGn-168 targets CD162 on activated T-Cells and has been licensed to Boehringer Ingelheim and is in Phase I testing for the treatment of autoimmune diseases. AbGenomics’ other candidates are all preclinical and oncology focused. It seeks to partner its products either after the preclinical or Phase II stage. The company has offices in both the US and Taiwan. 

    Taiwan Liposome Company (TLC) began operations in 1997. It focuses on developing novel liposome formulations of off-patent drugs, improving its performance by reducing the drug’s toxicity, improving its stability, targeting its delivery. With its technology, it has developed Lipo-Dox, licensed to TTY Biopharm for sale in multiple Asian countries. It has also built a pipeline of newly formulated drugs in various stages of development. TLC has a US office driving the development of its compound, Lipotecan- a novel Topotecan analog in its proprietary liposome formulation. The compound is in Phase I studies.

    Since the 1980s when the Taiwan government deemed biotech to be an important to the country, billions of dollars have been poured into industry. Industry however, has been slow to take root. We may have reached an inflection point. Generic drug companies have saturated the market, forcing drug makers to look for profit farther up the value chain. The large number of contract research organizations is now allowing small companies with nothing but an idea to outsource nearly all the necessary research, even conducting studies overseas.

    This set of four companies represents just the first wave of innovative biotechs coming out of Taiwan. 


    Disclosure: No Position
Back To Chimera Research Group's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (5)
Track new comments
  • John Tucker
    , contributor
    Comments (390) | Send Message
     
    Nice article Jason. I used to follow the CXCR4 area a few years back when I was on an HIV program. CXCR4 was being pursued by a couple of companies because it is one of three receptors used by HIV for cell entry (another is CCR5, which is targeted by a marketed Pfizer product, Selzentry).

     

    At the time, the main problem with CXCR4 as an HIV target was that the only lead structures that people were finding in their broad screens were crown ether-like polyamines that seemed likely to stick to every negatively charged surface in the body. I was quite surprised to see that one of these, AMD3100, is now an approved drug for stem cell mobilization. The side effect profile shown on the package insert seems to suggest it is too toxic for chronic use as would be needed in an HIV indication.

     

    So it would be interesting to know if the structure of TG-0054 has been published, whether it is another polyamine, and whether the toxicity of AMD3100 is mechanism-based or unique to its polyamine structure. The HIV market is quite a bit bigger than the autologous stem cell transplantation market.
    13 Aug 2010, 10:01 AM Reply Like
  • Chimera Research Group
    , contributor
    Comments (388) | Send Message
     
    Author’s reply » Seems you know a good bit about the subject. Only thing with CXCR4 is the drugs I see are all IV, may be tough to push.
    Didn't realize CXCR4 had so many functions, though. May be useful in autoimmue disease, I believe.

     

    Check out cmpds from Flexion Thera- a couple have eerily similar indications- no notes on target.
    14 Aug 2010, 03:22 PM Reply Like
  • Chimera Research Group
    , contributor
    Comments (388) | Send Message
     
    Author’s reply » Interesting, more CXCR4: invivoblog.blogspot.com/
    26 Aug 2010, 04:49 PM Reply Like
  • Sheff Station
    , contributor
    Comments (31) | Send Message
     
    Solid article Jason. The pharma market in Taiwan is severely undervalued IMO. Your ability to highlight the potential there was sound.
    1 Sep 2010, 05:27 PM Reply Like
  • Chimera Research Group
    , contributor
    Comments (388) | Send Message
     
    Author’s reply » Thanks Sheff-
    I believe in time Taiwan companies will come of age. We shall see.
    2 Sep 2010, 02:30 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • $CELG $CELG Abraxane ph 3 pancreatic cancer trial shows stat sig improvemnt in overall survival! Suggested this back in June for subscribrs
    Nov 10, 2012
  • We are big believers in $PCYC, $MDVN, $INCY, $SGEN and more.
    Jul 10, 2012
  • $CHTP: 700 call contracts traded today. speculative interest returning...?
    Aug 10, 2010
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.